McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health's (CAH) third-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
Besides Wall Street's top -and-bottom-line estimates for Cardinal (CAH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.